David A Fruman

List of Publications by Year
in descending order

107 papers	12,417 citations	36303 51 h-index	31849 101 g-index
186 all docs	186 docs citations	186 times ranked	15856 citing authors

#	Article	IF	Citations
1	Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax. British Journal of Cancer, 2021, 124, 1098-1109.	6.4	13
2	Targeting the Mevalonate Pathway in Cancer. Trends in Cancer, 2021, 7, 525-540.	7.4	50
3	A cross-institutional analysis of the effects of broadening trainee professional development on research productivity. PLoS Biology, 2021, 19, e3000956.	5.6	18
4	Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function. IScience, 2021, 24, 102748.	4.1	7
5	Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2021, 11, 673213.	2.8	9
6	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. Scientific Reports, 2021, 11, 21689.	3.3	2
7	YAP-mediated mechanotransduction tunes the macrophage inflammatory response. Science Advances, 2020, 6, .	10.3	127
8	A Case for Phosphoinositide 3-Kinaseâ€“Targeted Therapy for Infectious Disease. Journal of Immunology, 2020, 205, 3237-3245.	0.8	6
9	An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood, 2020, 135, 2337-2353.	1.4	49
10	Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. Nature Communications, 2020, 11, 3326.	12.8	57
11	Keys to successful implementation of a professional development program. , 2020, , 129-137.		2
12	Targeting PI3K-Gamma in Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37, 932-934.	1.6	7
13	The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes. Journal of Immunology, 2019, 202, 579-590.	0.8	20
14	The CD11a and Endothelial Protein C Receptor Marker Combination Simplifies and Improves the Purification of Mouse Hematopoietic Stem Cells. Stem Cells Translational Medicine, 2018, 7, 468-476.	3.3	3
15	Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism. Molecular Cancer Therapeutics, 2018, 17, 1781-1792.	4.1	19
16	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget, 2018, 9, 8027-8041.	1.8	42
17	Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine, 2018, 10, .	12.4	61
18	mTOR inhibition enhances efficacy of dasatinib in <i>ABL</i>-rearranged Ph-like B-ALL. Oncotarget, 2018, 9, 6562-6571.	1.8	15

#	Article	IF	Citations
19	A targeted treatment with off-target risks. Nature, 2017, 542, 424-425.	27.8	18
20	mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Molecular Cancer Therapeutics, 2017, 16, 1942-1953.	4.1	10
21	Silencing c-Myc translation as a therapeutic strategy through targeting PI3KÎ´ and CK1Îµ in hematological malignancies. Blood, 2017, 129, 88-99.	1.4	92
22	The PI3K Pathway in Human Disease. Cell, 2017, 170, 605-635.	28.9	1,702
23	The Selective Phosphoinoside-3-Kinase p110Î´ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Frontiers in Immunology, 2017, 8, 747.	4.8	21
24	Targeting mTOR for the treatment of B cell malignancies. British Journal of Clinical Pharmacology, 2016, 82, 1213-1228.	2.4	36
25	The 4E-BPâ€“eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Science Signaling, 2016, 9, ra57.	3.6	56
26	mTOR signaling: new networks for ALL. Blood, 2016, 127, 2658-2659.	1.4	5
27	Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation <i>via</i> Simultaneous Gene Transduction and Silencing. ACS Nano, 2016, 10, 8705-8714.	14.6	22
28	Context-Specific Function of S6K2 in Th Cell Differentiation. Journal of Immunology, 2016, 197, 3049-3058.	0.8	13
29	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. Blood, 2016, 128, 2763-2763.	1.4	5
30	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget, 2016, 7, 55083-55097.	1.8	31
31	Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 3969-3969.	1.4	0
32	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget, 2015, 6, 35202-35217.	1.8	23
33	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. Oncotarget, 2015, 6, 2088-2100.	1.8	30
34	INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency. Cancer Discovery, 2015, 5, 697-700.	9.4	17
35	Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1. PLoS ONE, 2014, 9, e88865.	2.5	37
36	Effects of Novel Isoform-Selective Phosphoinositide 3-Kinase Inhibitors on Natural Killer Cell Function. PLoS ONE, 2014, 9, e99486.	2.5	11

#	Article	IF	Citations
37	Idelalisib â€” A PI3KÎ´ Inhibitor for B-Cell Cancers. New England Journal of Medicine, 2014, 370, 1061-1062.	27.0	86
38	mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5076-85.	7.1	57
39	PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery, 2014, 13, 140-156.	46.4	1,398
40	Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. Journal of Clinical Investigation, 2014, 124, 3688-3690.	8.2	13
41	Can Cancer Drugs Treat Immunodeficiency?. Science, 2013, 342, 814-815.	12.6	7
42	Achieving cancer cell death with PI3K/mTORâ€targeted therapies. Annals of the New York Academy of Sciences, 2013, 1280, 15-18.	3.8	25
43	Selective Inhibition of Phosphoinositide 3-Kinase p110Î± Preserves Lymphocyte Function*. Journal of Biological Chemistry, 2013, 288, 5718-5731.	3.4	60
44	Targeting of the MNKâ€“eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2298-307.	7.1	132
45	Akt and mTOR in B Cell Activation and Differentiation. Frontiers in Immunology, 2012, 3, 228.	4.8	165
46	PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochemical Journal, 2012, 442, 465-481.	3.7	196
47	PrP. , 2012, , 1488-1488.		0
48	PI3KÎ´ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic. Cancer Discovery, 2011, 1, 562-572.	9.4	126
49	Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function. Blood, 2011, 118, 963-963.	1.4	1
50	The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models. Blood, 2011, 118, 2585-2585.	1.4	0
51	Foxo1 regulates marginal zone Bâ€cell development. European Journal of Immunology, 2010, 40, 1890-1896.	2.9	40
52	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine, 2010, 16, 205-213.	30.7	329
53	Phosphoinositide 3-Kinases. , 2010, , 1049-1060.		5
54	Target of Rapamycin Signaling in Leukemia and Lymphoma. Clinical Cancer Research, 2010, 16, 5374-5380.	7.0	44

#	Article	IF	Citations
55	Regulatory Subunits of Class IA PI3K. Current Topics in Microbiology and Immunology, 2010, 346, 225-244.	1.1	40
56	B Cell Receptor Signaling: Picky About PI3Ks. Science Signaling, 2010, 3, pe25.	3.6	12
57	PI3Ks in Lymphocyte Signaling and Development. Current Topics in Microbiology and Immunology, 2010, 346, 57-85.	1.1	55
58	Targeting TOR dependence in cancer. Oncotarget, 2010, 1, 69-76.	1.8	43
59	The p85Î² regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity, 2009, 42, 447-458.	2.6	16
60	Immune Regulation by Rapamycin: Moving Beyond T Cells. Science Signaling, 2009, 2, pe25.	3.6	40
61	Organâ€specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from geneâ€targeting of the PI3K regulatory isoforms p85Î±, p55Î±, and p50Î±. Developmental Dynamics, 2009, 238, 2670-2679.	1.8	54
62	Fine tuning the immune response with PI3K. Immunological Reviews, 2009, 228, 253-272.	6.0	191
63	p85Î² phosphoinositide 3-kinase regulates CD28 coreceptor function. Blood, 2009, 113, 3198-3208.	1.4	34
64	FOXO1 Regulates L-Selectin and a Network of Human T Cell Homing Molecules Downstream of Phosphatidylinositol 3-Kinase. Journal of Immunology, 2008, 181, 2980-2989.	0.8	181
65	Cancer therapy: staying current with AMPK. Biochemical Journal, 2008, 412, e3-e5.	3.7	16
66	KLF4 is a FOXO target gene that suppresses B cell proliferation. International Immunology, 2008, 20, 671-681.	4.0	66
67	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. Journal of Clinical Investigation, 2008, 118, 3038-3050.	8.2	148
68	Class IA Phosphoinositide 3-Kinase Modulates Basal Lymphocyte Motility in the Lymph Node. Journal of Immunology, 2007, 179, 2261-2269.	0.8	39
69	KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood, 2007, 109, 747-755.	1.4	59
70	T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood, 2007, 109, 2894-2902.	1.4	54
71	Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity, 2007, 40, 433-441.	2.6	16
72	Measuring Phosphorylated Akt and Other Phosphoinositide 3-kinase-Regulated Phosphoproteins in Primary Lymphocytes. Methods in Enzymology, 2007, 434, 131-154.	1.0	18

#	Article	IF	Citations
73	Distinct signaling mechanisms activate the target of rapamycin in response to different Bâ€cell stimuli. European Journal of Immunology, 2007, 37, 2923-2936.	2.9	74
74	FOXO Transcription Factors Cooperate with ÎEF1 to Activate Growth Suppressive Genes in B Lymphocytes. Journal of Immunology, 2006, 176, 2711-2721.	0.8	72
75	Sjogren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16882-16887.	7.1	68
76	Role of Phosphoinositide 3-Kinase Regulatory Isoforms in Development and Actin Rearrangement. Molecular and Cellular Biology, 2005, 25, 2593-2606.	2.3	120
77	ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors. Cancer Research, 2005, 65, 2047-2053.	0.9	141
78	Analysis of the Major Patterns of B Cell Gene Expression Changes in Response to Short-Term Stimulation with 33 Single Ligands. Journal of Immunology, 2004, 173, 7141-7149.	0.8	55
79	Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85Â. International Immunology, 2004, 16, 1789-1798.	4.0	28
80	Enhanced T Cell Proliferation in Mice Lacking the p85Î² Subunit of Phosphoinositide 3-Kinase. Journal of Immunology, 2004, 172, 6615-6625.	0.8	69
81	Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Current Opinion in Immunology, 2004, 16, 314-320.	5.5	121
82	Frontline: The p85? isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. European Journal of Immunology, 2004, 34, 2968-2976.	2.9	24
83	P<scp>hosphoinositide</scp>3-K<scp>inase</scp>: Diverse Roles in Immune Cell Activation. Annual Review of Immunology, 2004, 22, 563-598.	21.8	317
84	PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Seminars in Cell and Developmental Biology, 2004, 15, 183-197.	5.0	59
85	Optimal B-cell proliferation requires phosphoinositide 3-kinaseâ€"dependent inactivation of FOXO transcription factors. Blood, 2004, 104, 784-787.	1.4	125
86	Phosphoinositide 3-kinase signaling is essential for ABL oncogeneâ€"mediated transformation of B-lineage cells. Blood, 2004, 103, 4268-4275.	1.4	83
87	Regulation of quiescence in lymphocytes. Trends in Immunology, 2003, 24, 380-386.	6.8	178
88	Altered Signaling and Cell Cycle Regulation in Embryonal Stem Cells with a Disruption of the Gene for Phosphoinositide 3-Kinase Regulatory Subunit p85Î±. Journal of Biological Chemistry, 2003, 278, 5099-5108.	3.4	39
89	Positive and Negative Roles of p85Î± and p85Î² Regulatory Subunits of Phosphoinositide 3-Kinase in Insulin Signaling. Journal of Biological Chemistry, 2003, 278, 48453-48466.	3.4	183
90	Proliferation and Survival of Activated B Cells Requires Sustained Antigen Receptor Engagement and Phosphoinositide 3-Kinase Activation. Journal of Immunology, 2003, 170, 5851-5860.	0.8	85

#	Article	IF	Citations
91	Phosphoinositide 3-kinase and Bruton's tyrosine kinase regulate overlapping sets of genes in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 359-364.	7.1	61
92	Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival. Molecular and Cellular Biology, 2002, 22, 965-977.	2.3	254
93	Phosphoinositide 3-kinase in immunological systems. Seminars in Immunology, 2002, 14, 7-18.	5.6	193
94	Reduced expression of the murine p85Î± subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. Journal of Clinical Investigation, 2002, 109, 141-149.	8.2	183
95	Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85Î±. Nature Genetics, 2000, 26, 379-382.	21.4	273
96	Impaired Kit- but Not FcÎµRI-initiated Mast Cell Activation in the Absence of Phosphoinositide 3-Kinase p85Î± Gene Products. Journal of Biological Chemistry, 2000, 275, 6022-6029.	3.4	75
97	Xid-like Phenotypes. Immunity, 2000, 13, 1-3.	14.3	192
98	The SH2 Domain-containing Inositol 5â€²-Phosphatase (SHIP) Recruits the p85 Subunit of Phosphoinositide 3-Kinase during FcÎ³RIIb1-mediated Inhibition of B Cell Receptor Signaling. Journal of Biological Chemistry, 1999, 274, 7489-7494.	3.4	53
99	SYK Is Upstream of Phosphoinositide 3-Kinase in B Cell Receptor Signaling. Journal of Biological Chemistry, 1999, 274, 32662-32666.	3.4	164
100	PI 3-KINASE KNOCKOUT MICE: ROLE OF p85Î± IN B CELL DEVELOPMENT AND PROLIFERATION. Biochemical Society Transactions, 1999, 27, A73-A73.	3.4	0
101	Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO Journal, 1998, 17, 1961-1972.	7.8	418
102	PHOSPHOINOSITIDE KINASES. Annual Review of Biochemistry, 1998, 67, 481-507.	11.1	1,366
103	Transformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase. Science, 1997, 276, 1848-1850.	12.6	398
104	Structural Organization and Alternative Splicing of the Murine Phosphoinositide 3-Kinase p85Î± Gene. Genomics, 1996, 37, 113-121.	2.9	118
105	FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. European Journal of Immunology, 1995, 25, 563-571.	2.9	72
106	Immunophilins in protein folding and immunosuppression ¹. FASEB Journal, 1994, 8, 391-400.	0.5	248
107	Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas. European Journal of Immunology, 1992, 22, 2513-2517.	2.9	99